Greenhalgh, J <br/><br/>
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  May 2010 
 - 31-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta14Suppl1/05  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--drug therapy<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Clopidogrel<br/>Cost-Benefit Analysis<br/>Humans<br/>Models, Economic<br/>Piperazines--adverse effects<br/>Platelet Aggregation Inhibitors--economics<br/>Prasugrel Hydrochloride<br/>Purinergic P2Y Receptor Antagonists--adverse effects<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Risk Assessment<br/>Thiophenes--adverse effects<br/>Ticlopidine--adverse effects<br/>United Kingdom